Only a tenth of scripts are up for grabs, says IMS study

Share this article:
Traditional promotion efforts, including details and sampling, can only affect about 10% of prescriptions, an IMS study found, suggesting that the bulk of promotion dollars is misplaced.

The data firm's Brand Excellence Study looked at prescriptions for 50 brands across 10 categories and found a small “dynamic market” comprised of patients who are making changes to their therapeutic regimens. There's some slight variation between categories — for diabetes, new starts, add-ons and switches comprise around 5% of prescriptions, and for overactive bladder medications, at the other extreme, it's about 15% — but on average, only a tenth of prescriptions are capable of being influenced. That sliver, says IMS, is the make-or-break segment for product launches.

Around 60% of that dynamic market — or 6% of all scripts — is “new-to-therapy” starts, which IMS defines as patients not on any drug in that class for the past year. Another 30% is switches, with the remaining 10% made up of add-on therapies.

“Down at the patient level, these patients are entering the dynamic market for different reasons,” said Rob Harold, senior principal at IMS. “Depending on whether it's an asymptomatic or symptomatic disease, it could be the intensity of symptoms, it could be the number of symptoms, it could be a diagnostic test or screening that prompts the new start.” Switches indicate dissatisfaction with current therapy, whether for reasons of efficacy, adverse events, dosing, delivery mechanism or sticker shock, said Harold, noting: “We found that a strong reason for people entering the dynamic market is seeking a lower copay.”

The study found similar disparities in physicians' prescribing habits. Around 4% of physicians — some 24,000 dubbed “market drivers” by the study — wrote 44% of all new-to-brand prescriptions tracked. Another 409,000 “non-drivers,” around 90% of physicians to whom roughly 60% of field force contacts and samples are allocated, generated less than 40% of new-to-brand scripts.  

“There's that classic adage that says, ‘We know 50% of our budget is ineffective, we just don't know which 50%,'” said Harold. “We see over-allocation in that group, and the true market driver quadrant still receives some of the contacts but it's not proportionate. We know that prescribers in that 4% see more patients, they're making more changes, and as a result, they're more engaged with the field force.”  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...